Augmented trabeculectomy with mitomycin C in primary congenital glaucoma
Reviewed by Fiona Rowe

This study aimed to determine success of trabeculectomy augmented with mitomycin C (MMC) in children with primary congenital glaucoma (PCG) and document complications of this intervention. Over a two-year period, the authors treated 74 eyes of 42 children with PCG, aged 11.7 ±8.5 months of which 76% were under 12 months of age. There were 24 males and 18 females. Seventy-six percent had bilateral glaucoma and mean follow-up was 18.2 ±3.8 months. Results at one year were presented. Preoperative intraocular pressure (IOP) was 27.3 ±4.2mmHg reducing to postop 17.9 ±6.3mmHg. Absolute success was defined as IOP without medication <21mmHg and was achieved in 73 children (98.6%) at one month and 20 (27%) at one year. Qualified success was defined as IOP with medication <21mmHg and achieved in one child (1.4%) at one month and 36 (48.6%) at one year. Total success at one year was 75.7%. Complications occurred in 18 eyes including shallow anterior chamber, collapsed anterior chamber and choroidal detachment. Mean time of failure with uncontrolled IOP was 7.6 ±3.8 months and requiring further surgery. Short follow-up was a limitation for this study. The authors conclude augmented trabeculectomy is a useful primary procedure with good success rate, and can be supplemented where needed by topical medication.

Success rate of augmented trabeculectomy in primary congenital glaucoma.
Jabeen S, Noorani S, Memon MN, Zaheer N.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2022;59(3):180-6.